Intrathecal Nicardipine-Time to Treat the Symptom?
- PMID: 39715987
- DOI: 10.1007/s12028-024-02176-y
Intrathecal Nicardipine-Time to Treat the Symptom?
Conflict of interest statement
Conflicts of Interest: The authors have no conflicts to disclose. Ethical Approval/Informed Consent: We confirm that institutional review board approval was not required for this editorial.
References
-
- Qureshi AI, Lobanova I, Huang W, Ishfaq MF, Broderick JP, Cassarly CN, et al. Lessons learned from phase II and phase III trials investigating therapeutic agents for cerebral ischemia associated with aneurysmal subarachnoid hemorrhage. Neurocrit Care. 2022;36(2):662–71. - PubMed
-
- Sweeney JF, Chen J, Darwish B, Holden D, Barnes E, Varelas P. Intrathecal nicardipine after aneurysmal subarachnoid hemorrhage: a scoping review. Neurocrit Care. 2024. https://doi.org/10.1007/s12028-024-02175-z . - DOI - PubMed
-
- Hafeez S, Grandhi R. Systematic review of intrathecal nicardipine for the treatment of cerebral vasospasm in aneurysmal subarachnoid hemorrhage. Neurocrit Care. 2019;31(2):399–405. - PubMed
-
- Stuart D, Christian R, Uschmann H, Palokas M. Effectiveness of intrathecal nicardipine on cerebral vasospasm in non-traumatic subarachnoid hemorrhage: a systematic review. JBI Database Syst Rev Implement Rep. 2018;16(10):2013–26.
-
- Kramer AH, Zygun DA. Neurocritical care: why does it make a difference? Curr Opin Crit Care. 2014;20(2):174–81. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
